Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–137 of 137 matching trials from the live ClinicalTrials.gov search.
Conditions
Keratoconjunctivitis Sicca, Dry Eye
Interventions
Tavilermide ophthalmic solution, Placebo
Drug · Other
Lead sponsor
Mimetogen Pharmaceuticals USA, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 19 more
Conditions
Mydriasis, Dilation
Interventions
Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
4
States / cities
Pittsburg, Kansas • Lexington, Kentucky • Athens, Ohio + 1 more
Conditions
Herpes Labialis, Cold Sore
Interventions
SADBE, Placebo
Drug · Other
Lead sponsor
Squarex, LLC
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Redwood City, California • Doral, Florida • Boston, Massachusetts + 2 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion

NCT02061813
Conditions
Head Lice
Interventions
Abametapir Lotion 0.74% w/w, Sodium Lauryl Sulfate, Saline 0.9%, Placebo
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Paramus, New Jersey
Conditions
Androgenetic Alopecia
Interventions
Topical SM04554 solution, Topical vehicle solution
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Clinton Township, Michigan • Cleveland, Ohio • College Station, Texas + 2 more
Conditions
Distal Subungual Onychomycosis
Interventions
MOB015B, MOB015B Vehicle
Drug
Lead sponsor
Moberg Pharma AB
Industry
Eligibility
12 Years to 75 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Multiple Locations, California • Multiple Locations, Florida • Multiple Locations, Idaho + 6 more
Conditions
Actinic Keratosis
Interventions
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%, Vehicle containing excipients only (VEH) without active ingredient, Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E
Drug · Other · Device
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Fremont, California • Aventura, Florida • Rolling Meadows, Illinois + 7 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

NCT04513652
Conditions
Anesthesia, Local
Interventions
AG-920, Placebo
Drug
Lead sponsor
American Genomics, LLC
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Newport Beach, California
Conditions
Acute Otitis Media
Interventions
Moxidex otic solution, Moxifloxacin otic solution, Vehicle, Tympanostomy tubes
Drug · Other · Device
Lead sponsor
Alcon Research
Industry
Eligibility
6 Months to 12 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Fort Worth, Texas
Conditions
Decrease in Night Vision, Disturbance; Vision, Loss
Interventions
Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Lynbrook, New York
Conditions
Dry Eye
Interventions
HL036 Ophthalmic Solution, Placebo
Biological
Lead sponsor
HanAll BioPharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
12
States / cities
Phoenix, Arizona • Newport Beach, California • Torrance, California + 9 more
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
PF-04217329, latanoprost vehicle, latanoprost
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
8
States / cities
Cypress, California • Garden Grove, California • Gardena, California + 4 more
Conditions
Dry Eye
Interventions
0.25% Tanfanercept Ophthalmic Solution, Placebo
Drug
Lead sponsor
HanAll BioPharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Glendale, California • Newport Beach, California + 7 more
Completed Phase 3 Interventional Results available

Study Evaluating the Safety and Efficacy of AR-15512

NCT05285644
Conditions
Dry Eye Disease
Interventions
0.003% AR-15512 ophthalmic solution, AR-15512 vehicle ophthalmic solution
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
23
States / cities
Glendale, California • Torrance, California • Colorado Springs, Colorado + 19 more
Completed No phase listed Observational Accepts healthy volunteers

Spinal and Supra-Spinal Pain Mechanisms in Patients With Fibromyalgia

NCT03464292
Conditions
Fibromyalgia, Pain
Interventions
Capsaicin Patch 8% or 0.1% Capsaicin Cream, Vehicle Patch
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Completed Phase 3 Interventional Results available

Cantharidin Application in Molluscum Patients-1

NCT03377790
Conditions
Molluscum Contagiosum
Interventions
VP-102 - Cantharidin, Topical Film Forming Solution, Placebo -Topical Film Forming Solution without VP-102
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
2 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
18
States / cities
Birmingham, Alabama • Dothan, Alabama • Little Rock, Arkansas + 15 more
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
BOL-303259-X, Timolol
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, New York